Emcure Pharmaceuticals Limited vs Laurus Labs Limited
A side-by-side comparison of Emcure Pharmaceuticals Limited (EMCURE) and Laurus Labs Limited (LAURUSLABS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Emcure Pharmaceuticals Limited leads EMCURE vs LAURUSLABS on 11 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation40
- Profitability22
- Growth20
- Size & financial health31
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EMCURE takes 4/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
EvenHow efficiently each company turns capital and sales into profit. Higher is better.
Growth
EMCURE takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
EMCURE takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has delivered good profit growth of 17.6% CAGR over last 5 years"]
- − ["Stock is trading at 6.98 times its book value"]
- + []
- − ["Stock is trading at 21.00 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.